 BOSTON and ATLANTA , Nov. 8, 2022 PRNewswire -- Inhibikase Therapeutics, Inc. Nasdaq: IKT Inhibikase or Company, a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinsons disease, Parkinsons-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. 